Alexander, John http://orcid.org/0000-0003-3973-6501
Schipper, Koen
Nash, Sarah
Brough, Rachel
Kemp, Harriet
Iacovacci, Jacopo
Isacke, Clare http://orcid.org/0000-0002-9222-3345
Natrajan, Rachael http://orcid.org/0000-0002-9987-2946
Sawyer, Elinor http://orcid.org/0000-0001-8285-4111
Lord, Christopher J. http://orcid.org/0000-0002-3226-0515
Haider, Syed http://orcid.org/0000-0001-6685-5480
Funding for this research was provided by:
Breast Cancer Now
Article History
Received: 2 June 2023
Revised: 26 March 2024
Accepted: 3 April 2024
First Online: 10 April 2024
Competing interests
: CJL makes the following disclosures: receives and/or has received research funding from: AstraZeneca, Merck KGaA, Artios. Received consultancy, SAB membership or honoraria payments from: Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline. Has stock in: Tango, Ovibio, Hysplex, Tesselate. CJL is also a named inventor on patents describing the use of DNA repair inhibitors, including ATR inhibitors, and stands to gain from their development and use as part of the ICR “Rewards to Inventors” scheme and also reports benefits from this scheme associated with patents for PARP inhibitors paid into CJL’s personal account and research accounts at the Institute of Cancer Research. All other authors declare no competing interests.
: A retrospective series of primary untreated ILC tumours (<i>n</i> = 50) was obtained with appropriate ethical approval and consent from the Kings Health Partners tissue bank (London) with detailed clinical outcome and treatment data (REC Number: 12/EE/0493).